

WHO Pharmaceuticals Newsletter N1 2014
25 de marzo 2014

Indice

Regulatory Matters

Acetaminophen (Paracetamol INN)	4
Acipimox	4
Capecitabine	5
Clobazam	5
Duloxetine ---	5
Finasteride and dutasteride	6
Methylphenidate	6
Ofatumumab	7
Prasugrel	7
Recombinant interferon-beta	8
Regadenoson and adenosine	8
Rituximab	8
Rosiglitazone	8
Sodium Phosphate Over-the-Counter Products	9
Strontium ranelate	9
Temozolomide	10
Lenalidomide	10
Zolpidem tartrate	10

Safety of medicines

Clopidogrel	12
Minocycline	12
Pioglitazone	12
Ponatinib	13

Signal

Emtricitabine/Efavirenz/Tenofovir Disoproxil Fumarate and Phosphatase Alkaline Increased	14
Ibuprofen and Erectile Dysfunction	18
Parathyroid Hormone and Myocardial Ischaemia	21
Roflumilast and Pancreatitis	26
Vemurafenib and Granulocytopenia.....	30
The UMC Measures of Disproportionate Reporting	34
Feature	
Recommendations from the Thirty-sixth Annual Meeting of National Pharmacovigilance Centres	36

disponible en <http://bit.ly/1jqxiER>